Success of New Immunotherapy in Colorectal Cancer with BRAF Mutation
Results from clinical trials published in Nature Medicine show high efficacy of the combination of encorafenib and binimetinib in patients with BRAF-mutant colorectal cancer resistant to standard therapy. The targeted combination demonstrated a significant increase in time to disease progression compared to chemotherapy.
Analytical Review: Nature Medicine Publishes Data on Encorafenib and Binimetinib in BRAF-Mutant Colon Cancer
Analysis Date: May 29, 2026
[The Gist]: What Is Really Happening
On the surface, it's yet another confirmation that targeted therapy works in BRAF V600E-mutant colorectal cancer. Nature Medicine published results from clinical trials showing the efficacy of the combination of encorafenib and binimetinib (BRAF + MEK inhibitors) in patients resistant to standard therapy. The combination demonstrated increased time to progression compared to chemotherapy.
But the real story here isn't about victory. It's about the limits of targeted therapy and why BRAF V600E in the colon is not the same as BRAF V600E in melanoma.
The main non-obvious insight missing from headlines:
In melanoma, a single BRAF inhibitor (vemurafenib, dabrafenib) or a combination with a MEK inhibitor is enough to achieve a response. In colorectal cancer, a BRAF inhibitor alone doesn't work—triple blockade is needed: BRAF + EGFR (cetuximab) + MEK (binimetinib). And even with triple blockade, median progression-free survival is about 5 months, and overall survival is about 13 months. This is progress, but not a breakthrough. The reality is: BRAF V600E-mutant colorectal cancer remains one of the most aggressive subtypes, and we are only beginning to understand why it is so stubbornly resistant.
Timeline and Context
April 2020 — FDA approves encorafenib + cetuximab (BRAF + EGFR inhibitors) for second-line BRAF V600E-mutant metastatic colorectal cancer based on the BEACON CRC study. Median overall survival: 9.3 months vs. 5.4 months in the control group.
2020-2025 — Accumulation of real-world clinical data. A meta-analysis of six studies (487 patients) showed a median overall survival of 9.75 months on triple therapy (encorafenib + cetuximab + binimetinib).
February 2026 — Publication of the Japanese real-world study BEETS (203 patients). Result: median overall survival 12.9 months, progression-free survival 4.9 months on triple therapy.
May 2026 — Publication in Nature Medicine of data on the combination of encorafenib and binimetinib (without cetuximab) in patients with BRAF-mutant colorectal cancer resistant to standard therapy.
Key numbers not mentioned in press releases:
BEETS data (real-world clinical practice in Japan, 195 patients):
- Median overall survival (triple therapy): 12.9 months
- Median progression-free survival: 4.9 months
- Median overall survival (double therapy without binimetinib): 12.9 months
Note: double and triple therapy showed comparable overall survival (14.0 vs. 12.9 months after statistical correction, HR 0.87). Adding a MEK inhibitor did not provide a significant benefit in the overall population. The advantage of triple therapy was observed only in patients with "poor prognostic factors" — ECOG status ≥1, three or more metastatic sites, elevated C-reactive protein.
Who Wins and Who Loses
Absolute winner — Pfizer (holder of encorafenib rights in the US) and Pierre Fabre (in Europe). The combination of encorafenib + cetuximab (with or without binimetinib) has been the standard second-line therapy for BRAF V600E-mutant colorectal cancer since 2020. The new data from Nature Medicine and BEETS confirm this status and help refine who should receive triple therapy.
Winners — patients with BRAF V600E-mutant colon cancer. Their options are limited: standard chemotherapy yields a median survival of less than 12 months. Targeted therapy (encorafenib + cetuximab ± binimetinib) increases this to 12-14 months in the second-line setting. Even 3-4 additional months are significant.
Loser — old chemotherapy regimens (FOLFIRI + cetuximab). BEACON CRC showed superiority of encorafenib + cetuximab over irinotecan + cetuximab (median survival 9.3 vs. 5.4 months). Old regimens are becoming history.
Non-obvious loss — the very idea of triple therapy. BEETS data showed that adding binimetinib (MEK inhibitor) to encorafenib + cetuximab does not improve overall survival in the overall population (HR 0.87 after statistical correction). Toxicity is higher: grade ≥3 adverse events rate is 46%. Acneiform dermatitis, diarrhea — serious side effects requiring treatment interruption.
Loser — the combination of encorafenib and binimetinib without cetuximab. This combination (without EGFR blockade) is mentioned in your news. But BEACON CRC and BEETS data are clear: without cetuximab, efficacy drops sharply. The reason is that in colorectal cancer, BRAF inhibitor causes paradoxical activation of the EGFR pathway, and this activation must be blocked separately. The combination of BRAF+MEK without EGFR blockade is an incomplete regimen that should not be used.
What the Media Are Not Saying
First and most important. The publication in Nature Medicine likely refers to the combination of encorafenib and binimetinib (without cetuximab). But this combination is not the standard. Without EGFR blockade (cetuximab or panitumumab), efficacy drops sharply. The media may have missed this nuance, presenting the data as a "breakthrough," while in reality it confirms that only triple blockade works.
Second. The numbers are impressive only if you don't know the context. Median progression-free survival on triple therapy in real-world practice is 4.9 months. This means half of patients progress within less than 5 months after starting treatment. Yes, it's better than chemotherapy (1.5-2 months), but calling it a "success" is a stretch.
Third. The BEETS study (Japanese real-world study) showed that double and triple therapy have comparable survival. Triple therapy provides benefit only in the subgroup of patients with "poor prognostic factors" (ECOG ≥1, three or more metastases, elevated CRP). For everyone else, adding binimetinib is additional toxicity without additional benefit.
Fourth. The rate of serious adverse events (grade ≥3) on triple therapy is 46%. Acneiform dermatitis and diarrhea are the most common. These are not "mild rashes." They are conditions that may require hospitalization, dose reductions, or treatment interruption. In real-world practice, only 60-70% of patients complete the full course without serious complications.
Fifth. BRAF V600E-mutant colorectal cancer accounts for only 8-12% of all cases. It is a small subgroup. The commercial potential is limited. For pharmaceutical companies, it's an orphan market. For patients, it's an important but still small step forward.
Forecast: Next 30 Days and 90 Days
30 days:
At ASCO 2026, updated data from BEACON CRC (long-term survival) and real-world cohorts from Europe and the US will likely be presented. Key questions: (1) Does triple therapy improve survival compared to double therapy in poor prognosis subgroups? (2) What is the resistance profile after progression on encorafenib + cetuximab?
National guidelines NCCN and ESMO already include encorafenib + cetuximab (with or without binimetinib) as standard second-line therapy for BRAF V600E-mutant colorectal cancer. The new data from Nature Medicine will not change these recommendations—they will only confirm them.
90 days:
Initial data on combinations with new agents will emerge. The BEAVER trial showed that in patients with non-V600E BRAF mutations (class 2 and 3), encorafenib + binimetinib is ineffective (ORR 14%, endpoint not met). But what's interesting is that researchers discovered resistance mechanisms, including CDK4/6 and SHP2. In preclinical models, adding CDK4/6 or SHP2 inhibitors to BRAF/MEK therapy restored sensitivity.
This opens the door to new clinical trials: triple therapy (BRAF + MEK + CDK4/6) for non-V600E mutations and for V600E with acquired resistance. If these trials show success (likely no earlier than 2028-2029), the market for targeted therapy of BRAF-mutant tumors will expand from 8-12% to 30% of all colorectal cancers.
Long-term forecast (2026-2028):
Encorafenib + cetuximab (with binimetinib in the poor prognosis subgroup) will remain the standard second-line therapy for BRAF V600E-mutant colorectal cancer. But this is not enough. Median survival of 12-14 months is not a "cure" or even "long-term control."
The main hopes now lie with combining targeted therapy and chemotherapy in the first line. The BREAKWATER study (encorafenib + cetuximab + mFOLFOX6) showed a median overall survival of 30.3 months vs. 15.1 months in the control group—that's serious progress. But this data is for first-line, not for resistant patients as mentioned in your news.
And finally: don't believe headlines about a "breakthrough in treating resistant cancer." Yes, we have advanced. Yes, patients live longer. But BRAF V600E-mutant colorectal cancer remains one of the most aggressive and difficult-to-treat subtypes. Triple blockade (BRAF + EGFR + MEK) is the best we have. But "best" still means progression in most patients within 5-6 months. The real breakthrough will happen when we understand why these tumors acquire resistance so quickly and learn to prevent it. For now, we are only at the beginning of this journey.
— Editorial Team
